USA flag logo/image

An Official Website of the United States Government

LAYERED MEMBRANES IN PROTEOMIC PROFILING OF RENAL CANC*

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70641
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
CA106685
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
20/20 GENESYSTEMS, INC.
9430 Key West Ave. Suite 100 ROCKVILLE, MD 20850-6347
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: LAYERED MEMBRANES IN PROTEOMIC PROFILING OF RENAL CANC*
Agency: HHS
Contract: 1R43CA106685-01
Award Amount: $79,501.00
 

Abstract:

DESCRIPTION (provided by applicant) "Personalized medicine" is a new clinical paradigm where a specific cancer therapeutic ("smart drug") is prescribed based upon the individual biology of the patient. A goal of personalized medicine is to select individual therapies based upon the correlation of proteomic profiles from diseased tissues with patient response to drug therapy. Therefore, there is a critical need for a practical tool that can generate protein expression profiles from small amounts of tissue samples collected from patients. We hypothesize that cancer patients will be treated more successfully if a correlation between proteomic profiles and drug efficacy is established and that a diagnostic test using our innovative and novel technology, Layered Protein Scanning (LPS), will be able to establish that correlation. The long-term goal of this proposal is to, by the end of Phase II, develop a clinical diagnostic tool that would be used to select and monitor patients most likely to respond to "smart drugs". We will initially focus on clear cell renal carcinoma patients being treated with inhibitors of Epidermal Growth Factor Receptor (EGFr) signaling. To establish proof of principle, in Phase I, we will test the ability of LPS to profile EGFr activity in clear cell renal carcinoma cell lines and tissues. Specifically, we will use LPS to quantitate differences in the levels of total EGFr, activated EGFr, total Erk1/2, activated Erk1/2, total TGF-alpha, and total VHL in: 1) Cell line samples (by comparing LPS-tissue blot with standard western blot) 2) Tissue sections of RCC (by comparing LPS-tissue blot to immunohistochemistry).

Principal Investigator:

Vladimir Knezevic

Business Contact:

Jonathan Cohen
3014242032
GCOHEN@2020GENE.COM
Small Business Information at Submission:

TWENTY-TWENTY GENE SYSTEMS
TWENTY-TWENTY GENE SYSTEMS 113 N WASHINGTON ST, #424 ROCKVILLE, MD 20850

EIN/Tax ID: 522272107
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No